Uncategorized
Aflibercept helps flatten persistent pigment epithelial detachments
Both retinal pigment epithelium height and central subfield thickness were reduced in patients with persistent retinal fluid whose treatment was switched to aflibercept from another intravitreal anti-VEGF, according to a study. Visual acuity, however, tended to worsen at 1 year after the change.The retrospective, comparative case series included 40 eyes of 37 patients with retinal pigment epithelial detachments (PEDs) whose treatment was switched to Eylea (aflibercept, Regeneron) from either Lucentis (ranibizumab, Genentech) or Avastin (bevacizumab, Genentech).